In This Section

Contact
E-mail
samelsonjonesb [at] chop.edu
Phone
Location - People View
5th Floor, Room 5028

3501 Civic Center Blvd
Philadelphia, PA 19104
United States

Research Topics
Benjamin J. Samelson-Jones, MD, PhD
Benjamin J. Samelson-Jones
Assistant Professor of Pediatrics

Dr. Samelson-Jones is a pediatric hematologist dedicated to improving the lives of children with bleeding and clotting disorders. His research focuses on gene therapy for hemophilia, the biochemical basis of coagulation, and the immune responses to hemophilia therapies.

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

Bio

Dr. Samelson-Jones is a pediatric hematologist dedicated to improving the lives of children with bleeding and clotting disorders. He received his doctorate training in protein biophysics at Albert Einstein College of Medicine where he provided the first molecular description of the interaction between nitric oxide and indoleamine 2,3-dioxygenase, a critical enzyme in immune tolerance. He completed clinical training at the Children’s National Medical Center and Children’s Hospital of Philadelphia.

His research at CHOP helped establish the gain-of-function coagulation factor IX variant Padua as the standard transgene for gene therapy for hemophilia B. He was the first to characterize the biochemical basis of the hyperactivity of factor IX Padua, and he helped run the first successful clinical gene therapy trial using factor IX Padua. The first regulatory approved gene therapeutics for hemophilia B are anticipated to use factor IX Padua.

Dr. Samelson-Jones has also studied other approaches to improve gene therapy for hemophilia. He delineated a deleterious interaction between the intracellular protease furin and coagulation factor VIII and demonstrated that bioengineering factor VIII to avoid furin improves gene therapy for hemophilia A. He has also investigated the consequences of immunosuppression on adeno associated viral vector gene therapy and established that concomitant intensive T cell directed immunosuppression and vector administration increases the risk of immune complications.

Education and Training

BA, Amherst College (Physics), 2001

MD, Albert Einstein College of Medicine, 2009

PhD, Albert Einstein College of Medicine (Biophysics), 2009

Pediatric Residency, Children's National Medical Center, 2012

Hematology and Oncology Fellowship, Children's Hospital of Philadelphia, 2015

Titles and Academic Titles

Assistant Professor of Pediatrics

Professional Memberships

Phi Beta Kappa, 2001-

Sigma Xi, 2001-

American Academy of Pediatrics, 2009-

American Society of Hematology, 2012-

American Society of Pediatric Hematology and Oncology, 2012-

The American Board of Pediatrics, 2013-

Hemostasis and Thrombosis Research Society, 2014-

International Society of Thrombosis and Haemostasis, 2015-

American Society of Gene and Cell Therapy, 2015-

The American Board of Pediatrics and its Sub-board of Pediatric Hematology-Oncology, 2017-

Professional Awards

The Basset Physics Prize, 1999

Dean of Faculty Fellowship for Student Research, 2000

The William Warren Stifler Physics Prize, 2001

Society of Porphyrins and Phthalocyanines Student Assistance Grant, 2006

Medical Student Teaching Award, 2011

Thrombosis-Hemostasis Summit of North America (THSNA) Travel Award, 2014

Children’s Hospital of Philadelphia Research Poster Day Prize, 2015

Outstanding Poster Presentation Award, American Society of Gene and Cell Therapy, 2018

Thrombosis-Hemostasis Summit of North America (THSNA) Young Investigator Award, 2020

Publication Highlights

Samelson-Jones BJ, Finn JD, Favaro P, Wright JF, Arruda VR. Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates. Mol Ther Methods Clin Dev. 2020 May; 17:1129-1138. PMID: 32490034
Samelson-Jones BJ, Finn JD, George LA, Camire RM, Arruda VR1. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity. JCI Insight. 2019 Jan; 5(14). PubMed PMID: 31219805
George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. 2017 Dec; 377(23):2215-2227. PMID: 29211678
Siner JI, Samelson-Jones BJ, Crudele JM, French RA, Lee BJ, Zhou S, Merricks E, Raymer R, Nichols TC, Camire RM, Arruda VR. Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models. JCI Insight. 2016 Oct; 1(16):e89371. PMID: 27734034
Samelson-Jones BJ, Yeh SR. Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul; 45(28):8527-38. PMID: 16834326

Active Grants/Contracts

Rational Development of Bioengineered Factor IX Variants
NIH/NHLBI
2018-2022

Work in this proposal would develop and characterize the biochemistry of hyperactive FIX variants, extensively evaluate their efficacy as protein and gene therapeutics for hemophilia B in a large gene deletion hemophilia B mouse model, and evaluate their immunogenicity in several distinct hemophilia B mouse models to test the role of the underlying FIX-gene mutation on tolerance to FIX variants.

PI: Samelson-Jones

Characterization of the Functional Repertoire and ontogeny of FVIII Humor Response Across Species
NIH/NHLBI
2018-2023

The goal of this project is to characterize, in depth, the Factor VIII inhibitor response in humans and dogs with severe Hemophilia A and define the role of emerging B cell survival cytokine.

PI: Arruda

New Technologies for Defining the Factor VIII Inhibitor Response
University of Pennsylvania Hemophilia Treatment Center
2019-2021

The goal of this proposal is to establish novel technologies that will enable comprehensive study of FVIII-specific B cells and antibodies.

PI: Samelson-Jones and Bhoj